BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | Feb 20, 2012
Financial News

HBM Partners financial update

HBM Partners completed a €90 million ($117.6 million) first close of its HBM BioCapital II fund that will invest in revenue-generating life sciences companies. The firm expects a final close of €120-€150 million ($156.8-$196 million)...
BioCentury | Feb 14, 2012
Financial News

HBM raises EUR 90M for new fund

HBM Partners raised EUR 90 million ($117.6 million) in the first close of its HBM BioCapital II fund, which will invest in revenue-generating life sciences companies. HBM expects a final close of EUR 120-EUR 150...
BioCentury | Feb 13, 2012
Finance

The allure of revenues

HBM Partners ' track record of eight exits from 15 investments in its first fund clearly gained the attention of LPs, as the firm has completed a €90 million ($117.6 million) first close on a...
BioCentury | Apr 2, 2007
Company News

Harvard Bio, Nanoentek Inc. sales and marketing update

HBIO's BTX Harvard Apparatus subsidiary granted Nanoentek's Digital Bio subsidiary exclusive distribution rights to electroporation products for gene delivery in certain Asian countries. Also, Digital Bio granted BTX Harvard exclusive distribution rights to Microporator, a...
Items per page:
1 - 5 of 5
BioCentury | Jul 30, 2020
Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies. Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check...
BioCentury | Feb 20, 2012
Financial News

HBM Partners financial update

HBM Partners completed a €90 million ($117.6 million) first close of its HBM BioCapital II fund that will invest in revenue-generating life sciences companies. The firm expects a final close of €120-€150 million ($156.8-$196 million)...
BioCentury | Feb 14, 2012
Financial News

HBM raises EUR 90M for new fund

HBM Partners raised EUR 90 million ($117.6 million) in the first close of its HBM BioCapital II fund, which will invest in revenue-generating life sciences companies. HBM expects a final close of EUR 120-EUR 150...
BioCentury | Feb 13, 2012
Finance

The allure of revenues

HBM Partners ' track record of eight exits from 15 investments in its first fund clearly gained the attention of LPs, as the firm has completed a €90 million ($117.6 million) first close on a...
BioCentury | Apr 2, 2007
Company News

Harvard Bio, Nanoentek Inc. sales and marketing update

HBIO's BTX Harvard Apparatus subsidiary granted Nanoentek's Digital Bio subsidiary exclusive distribution rights to electroporation products for gene delivery in certain Asian countries. Also, Digital Bio granted BTX Harvard exclusive distribution rights to Microporator, a...
Items per page:
1 - 5 of 5